Company Disclosure
GlaxoSmithKline Pharmaceuticals Limited (GSK) submitted a formal clarification to BSE Limited and The National Stock Exchange of India Limited regarding a significant increase in trading volume of its securities.
Nature of Event
This communication is in response to an email from the exchanges dated August 26, 2026, seeking clarification on the significant volume increase observed across exchanges in the recent past.
Company Response & Compliance Status
The company stated that it has made all necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from time to time. GSK confirmed that it has not withheld any material information or event that would have a bearing on the company's operations or performance, including all price-sensitive information.
Reason for Volume Increase
The company attributed the significant volume increase purely to market-driven factors, with no company-specific undisclosed developments causing the activity.
Future Commitment
GSK reiterated its commitment to continue complying with listing regulation requirements and to keep the stock exchanges informed of all price-sensitive information as and when they arise.